First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics

AIMS: Neuronal hypersensitisation due to adenosine triphosphate‐dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first‐in‐human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Stefan, Gashaw, Isabella, Baumann, Sybille, Chang, Xinying, Hummel, Thomas, Thuß, Uwe, Friedrich, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546310/
https://www.ncbi.nlm.nih.gov/pubmed/35437837
http://dx.doi.org/10.1111/bcp.15358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546310/
https://www.ncbi.nlm.nih.gov/pubmed/35437837
http://dx.doi.org/10.1111/bcp.15358

Ejemplares similares